Clinical Trial Update: Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial ARGSARC evaluating ADI-PEG 20 or placebo plus gemcitabine and docetaxel in previously treated leiomyosarcoma (soft tissue sarcoma) is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leiomyosarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• ADI-PEG 20 (pegylated arginine deiminase)
• Gemzar (gemcitabine)
• Taxotere (docetaxel)

Snippet

Sponsor: Polaris Group | Conditions: Soft Tissue Sarcoma | Phase 3 | Status: RECRUITING